What role does genetics play in altitude sickness susceptibility?

Genetic Factors Contributing to Altitude Sickness Susceptibility

Research has identified several genetic variants that increase the risk of altitude sickness. The EPAS1 gene, in particular, plays a crucial role in regulating the body’s response to high altitudes. Polymorphisms in the EPAS1 gene, specifically the rs11894252 allele, have been associated with a higher risk of acute mountain sickness (AMS). This variant affects the body’s ability to produce erythropoietin, a hormone that stimulates red blood cell production. At high altitudes, the body needs to produce more red blood cells to compensate for the lower oxygen levels. Individuals with the rs11894252 allele may not be able to produce enough red blood cells, leading to altitude sickness.

Predicting Susceptibility to Altitude Sickness

Genetic testing can help identify individuals who may be at risk of altitude sickness. A study conducted on climbers attempting to summit Mount Everest found that those with the rs11894252 allele were more likely to experience AMS. While genetic testing can provide valuable information, it is essential to note that altitude sickness is a multifactorial condition, and other factors such as physical conditioning, rate of ascent, and individual tolerance also play a significant role.

Managing Altitude Sickness Risk

Understanding genetic susceptibility can help climbers and travelers take preventive measures to minimize the risk of altitude sickness. For example, individuals with a known genetic risk may need to ascend to high altitudes more gradually, taking longer to acclimate to the lower oxygen levels. This can be done by splitting the ascent into multiple days or by taking rest days at intermediate altitudes. Additionally, individuals with a genetic risk may benefit from taking medications that help increase red blood cell production, such as erythropoietin-stimulating agents.